Johnson & Johnson and Royalty Pharma have entered into a $500 million research‑and‑development co‑funding agreement to advance JNJ‑4804, a novel antibody that simultaneously blocks interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways in autoimmune diseases.
The partnership provides J&J with a substantial capital infusion to support the clinical development of JNJ‑4804, a dual‑target biologic that could address unmet needs in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Royalty Pharma, a leading funder of innovation in the biopharmaceutical industry, will receive access to J&J’s manufacturing and commercialization expertise, potentially accelerating the drug’s path to market.
JNJ‑4804 is currently in Phase 2 studies for ulcerative colitis, psoriatic arthritis, and Crohn’s disease. The $500 million commitment is to be provided over 2026 and 2027, underscoring J&J’s strategy to expand high‑margin, high‑growth therapeutic areas and diversify its pipeline beyond existing IL‑23 and IL‑17 agents.
"We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ‑4804," said Pablo Legorreta, CEO and Chairman of Royalty Pharma. "Royalty Pharma has a strong track record of investing in immunology, beginning with early disease‑modifying biologics including TNF inhibitors. Johnson & Johnson is a recognized leader in immunology and we believe JNJ‑4804 holds substantial promise for patients with chronic immune‑mediated diseases. We see this as an exciting opportunity that builds on our commitment to partnering with global biopharma companies."
The partnership aligns with J&J’s broader immunology portfolio, which includes Stelara, Tremfya, and nipocalimab. Following the loss of exclusivity for Stelara, J&J is focusing on new drugs to offset revenue decline. By securing non‑dilutive capital from Royalty Pharma, J&J can accelerate development while preserving equity. Royalty Pharma’s model of providing upfront capital in exchange for future royalties positions the company to benefit from JNJ‑4804’s potential commercial success.
Shares of Royalty Pharma rose 1.4% in pre‑market trading after the announcement, reflecting investor confidence in the $500 million co‑funding deal and the promising dual‑target therapy.
The deal represents a significant financing event for both companies, reinforcing J&J’s commitment to next‑generation biologics and Royalty Pharma’s strategy of partnering with global biopharma companies to generate future revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.